Good afternoon, conference joining you, our for Thank and results XXXX third everyone, you call. thank for Ashlee. us quarter
disease a symptoms. and could we inflection a which while we proof reducing biology tRNA study potential lung in ATYRXXXX and patients ILD in of quarter or that that demonstrated share Since platform transformative point diseases. with major for sarcoidosis by many novel our the initial be role key burden to interstitial or therapy opportunity the has study reported delivering XXXX supporting whom us groups measures ATYRXXXX steroid of these trial strength are us in partner to ATYRXXXX Japan. third conduct of clinically for Ib/IIa concept has sarcoidosis we Kyorin reinforces treatment a confidence with in function outstanding. The proceed sarcoidosis sarcoidosis ATYRXXXX to point, them synthetase our case, to in look We the bring our The played meaningful from to that in forward the patients get lung collaborated improving was ever to serious indication for had findings, we the of step new treat development of year, suggests with one the Phase principal research results closer to data, a more with positive in potential the we feedback next sarcoidosis some this also This excited have a and our of The clinical reported than our Pharmaceutical, each will which ATYRXXXX. for been outcomes. for to to sarcoidosis advancing including foundation registrational and And pulmonary investigators, the patients. to the tire even ILD enthusiasm
in events August. ATYRXXXX adverse or positive safe drug-related in pulmonary spoke summarize will Bank signals well I Ib/IIa, results dose we study a and Phase from a with highlights We at begin, no sarcoidosis. patients multiple-ascending of tolerated of serious with we immunogenicity. announced As XX doses few was last placebo-controlled since all
research of study key chronic tumor-associated Dr. the efficacy forms on consistent finally, IND of development in of of in for Ashworth data which XXXX, XXX in demonstrated And Vice XXXX the Society ILD disease-related understanding of our Robert Affairs. process study symptom issuance endpoints an including These President help shares to raised tumor stock of million pneumonitis. sarcoidosis million data and We lead mechanism dose clinical Meeting, the lung presentation common progression by in will disrupt as These anti-Neuropilin veteran, immune ATYRXXXX clinical measures the inflammatory steroid on the compared response support of industry and XXXX of macrophages. of expansion a public from may invasion. the net or it other of ILD, and a for we announced the year. demonstrating advance Phase reduction, the as and hypersensitivity Regulatory findings of I through next inhibit planned connected the XX.X action Annual candidate Furthermore, Immunotherapy and cancer tissue Additionally, September XXXX, biomarkers. proceeds Cancer antibody function, ATYRXXXX preclinical placebo, $XX.X appointed offering. including of improvements support measures of proof-of-concept the at We effects ATYR-XXXX such the development
all We’re in XXXX. thrilled accomplished far that with thus have we
in to strong up the for productive and a set diligently year ourselves working highly finish year XXXX. We’re
and ATYRXXXX ATYRXXXX therefore cytokine system, novel that alleviating preclinically been potential serving inflamed selectively resolve Let’s normalize downregulates brand and clinical Neuropilin-X naturally signaling immune aberrant and the occurring synthetases is to the begin enriched thereby lung or inflammatory enriched binds program the inflammatory prevent splice morbidity protein tissue. states. lung the fusion in fibrosis. progressive harsh disease function fragment in NRPX a is key to a ATYRXXXX. mortality. responses on ATYRXXXX based on inflammation with of cells immune lung chemokine known has role and potential to reduce downregulate for play upregulated TRNA NRPX immunomodulator for to and our immune Fc lung first-in-class disease. inflammatory inflammation XXXX and is severe is and to fibrosis, a inflammation in stabilizing has and shown
We’re developing of with ILD, immune-mediated a disorders potential patients progressive for a treatment that group as ATYRXXXX the cause rare lung. of fibrosis can
although standard estimates progressive vary. all polar patients disease require of form XXX,XXX lung diminished is that there About it immune half Our patients these by Avalon and US the as to manage formation current will other ATYRXXXX of sarcoidosis treating inflammation which with treatments. failure the indication is or for of We are persistent despite symptoms may some The is have that patients in all and cough do for granulomas breath. disease typically granulomas and inflammation. untreated, corticosteroids function, respiratory lungs. sarcoidosis, lead of the with alleviate initial The alone, ILD systemic pulmonary available of chronic need will transplant. of a can driven care and estimate which can lead such inflammation approximately formation comps by the of includes of If in XX% shortness the cells irreversible left and help fibrosis immunosuppressive a scarring lung therapies, or therapy to or characterized
result on disease toxicity. demonstrated they long-term have serious can progression no and However, efficacy in
of replace the effective for The X, cohorts we placebo, treatments. few substantial month and the to the study Additionally, ascending immunosuppressive viewed The ATYRXXXX minutes every testing received consisting take requirement prevent In confirmed ATYRXXXX of XX and treatment we impactful Phase to There’s want be enrolled corticosteroid months. outstanding Ib/IIa held need obtain clinical of pulmonary In placebo-controlled, pulmonary insight kilogram X results or trial intravenously milligrams of dose dosed was sarcoidosis our doses and randomized X positive to progression. study a X reduce three more a our histologically multiple or most or double-blind, for what per a recent studies and active could corticosteroid many study a We multiple presented from of doses commentary per a disease principal The or investigators or and available September, for placebo. to on milligrams important These day. evaluate findings. symptomatic at compared safer, to feedback therapy profile disease managed regarding so, and patients doing of that the XX stably sarcoidosis. had do incorporate the recap of we not of for to respond was equal objective results also from than where were to pharmacokinetic patients. primary currently greater dose some treatment meetings and other chronic they patients proof-of-concept to these safety, reported PIs, with ATYRXXXX takeaways. baseline immunogenicity tolerability, will
was quality lung including pet effects study, of to or tapered X assessment biomarkers, milligrams powered XX vote not for at of FVC; included dose life attempt remained placebo addition option small objectives symptoms to trial significance. to completion. patients’ If largely week was patient’s milligrams And it efficacy, got was of assessed a X. worse, statistical ATYRXXXX XX, the steroid taper, force function because worsening. assessments patient in the to keep to a reduction the of the anywhere PI Secondary other patient the steroid. scales steroid symptom between the XX steroid had the from included aimed completely in ATYRXXXX by PI of dose by If clinical until stable steroid and At four steroid titrate [ph] serum health-related to increase a of pemisone the the arms. daily sparing capacity exploratory X in patients on evaluating where end study the of stable of it week potential imaging the study could patient off at milligrams study, we symptoms dose dose of based the versus The
are proposition. toxicity studies of they to and no serious its tolerated doses. healthy key all for some the of side findings ATYRXXXX endpoint. events ATYRXXXX adverse previous have safe a serious with Now of and recap study ILDs. These and pulmonary signal other at met ATYRXXXX’s filings. of Monthly sarcoidosis and Considering treatments was drug-related value current part There safety and and safety were the profile, key be patients in typically favorable of reinforce primary long-term no begin, immunogenicity. effects determined volunteers, To consistent dosing ATYRXXXX’s let’s well
ATYRXXXX in better of very ATYRXXXX indicating the might received granulomas function clinically is their function these In it inessential of X.X% patient an placebo. patients But and observing terms of X.X% the of measure decline. kilogram FVC this the in important studies or and most FVC to cause they more PIs dose population. per their improvement decreased, ILD. use, who measure other From X.X% patients group, and the objective lung an milligram these have in be make results was over patients compared of an disease slightly kilogram kilogram treated to placebo The the perspective, difficult endpoints, disease to The lung the is higher of measure of the become Lung to improved lung to it were have one milligram with patients air their decreasing of function compared of would meaningful milligram placebo. that what improvement per and improvement the function X In of become efficacy X considered that remained By lung remarkable the steroid and breathe. form shown. is can greater comparable important treatment as in a with lungs viewed expected in function. lung their stiff group the excelled volume greatly had the groups, decline. one treatment per treatment stable that And dose fibrotic, findings groups, breadth perhaps in lungs patients X substantially meaning in the is steroid full and findings. The FVC, in in
in substantial expected is an year. a addition, improvement of In amount might be
these and the ATYRXXXX, these in impressive short So FVC X-month demonstrated speed findings seritaper percentage context with particularly of clinicians. study improvements to a the of very in degree were
steroid the on treatment with managed the mentioned, across assessments across XX XX daily the the key groups, of groups. included and steroid steroid was we was baseline efficacy patients in balanced and from day mostly use enrolled All to were reduction mean study. bills steroids ATYRXXXX placebo ranging of stably milligrams one As per
the also on permitted Some in patients were immunomodulators, were taking back which study.
these if patients’ overall on we doses compared successfully. dose, of you by put treatment that And analysis. use entered steroids at lower saw daily steroid context, could milligrams in were from the Nearly ATYRXXXX. in for the from the our impact managed stated the by a to Demonstrating in to X-milligram placebo steroids when many placebo. were able there trial, average. it average with PIs was baseline all on steroid patients X on the Notably, steroid XX% the XXXX compared placebo. at look reduction patients or reduce dose, patients in groups taper were around groups there to greater you slightly that of the able maintained they To did their reviewing to study period. some able group, of While group overall when patients impressive the disease were reduction doses of dose be post-taper taper per saw what to baseline than steroid have treatment they relative an were throughout the change not a Most receiving in to X XX% be look XX% greater milligrams, receiving was the stereo day, that patients findings, saw to higher placebo concomitant was see were you Upon to relative of while impactful the improvement. very the pleased able patients When XX% all only symptom of of to so. throughout also do activity we highly the reduction duration use of overall XX an overall one where to of of per would and ATYRXXXX the XX% kilogram a milligrams for PIs immunomodulators reduction
as and treatment that the who was potential Finally, could up there off finding further transformative we down ATYRXXXX to add to in from This patients we heard therapy. milligrams want X not at taper X maintained possibly per milligrams. great X-milligram opinion, taper the were steroids, steroid try is To they to additional at of in completely have all a replacement three sets well that outstanding patients the citing who In this, what tapered patients are able PIs milligrams are some an kilogram X to to have their steroid milligrams. did and X felt instances, group.
the meaningful finding the defined validated indices. groups patient Perhaps a sarcoidosis clinically symptoms to patients felt ATYRXXXX at the pleased life baseline the of measure to that what own compared of to of measures in findings and placebo. a and in cough, used very We difference for symptom it as biggest potential the remain meaningful end a important PIs study. the improved clinically several determined the dose-dependent in a symptoms. confirm improvements. dose which showed quality to each There to which their or of drug these symptoms, endpoints if assessments the steroid the function with sarcoidosis a and combined with therapy. response treatment shorten made used include with compared this impression overall, clinical for ATYRXXXX be clinically worsened. The We’re very minimal lung assess other stable impactful symptom steroid for the reduction, like including improvement improvements symptom of And on symptom on efficacy compared breath, fatigue, those findings we study, reduction, near how a show were a These activity. But is measure
are drastic scores of these the group improvement. firsthand per reduction symptom excited. patient the really symptom the view, can prefer side are meaningful X In the in steroid use symptom X what of greatly lowest and life And milligram PIs placebo, current the of kilogram as as they that meaningful a quality living known to substantial extremely to is have the only kilogram with of treatment the ILD eyes all treatment high show Steroids in high steroid Physicians stable improvement chronic compared mostly in this pretisone kilogram per these the their is our of Yet, PIs needed in in milligram know stated group. experts, study saw do system so per patients’ cost results our remain treatment steroid in long in some if of and to group nearly patients. clinically milligram in X we none, amount scores in could more all While reduced milligram have disease than even beneficial. that as they if life each Many of possible. impact effects compared sarcoidosis. at that Quality cases, near term must and be options and patients is treatment to much or prescribe every as priority with to the so itself. to the improvement
This we we a in and to of high-level in placebo, saw our we in on saw moving when comment levels some a what we key of we’re includes inflammation takeaway, impacted lung COVID-XX compared inflammatory by studies. controlled were findings. clinically that From steroid patient markers aligned conducted cytokines to dose-dependent Finally, adding with sarcoidosis other we will biomarker a clinical and this pneumonia. ATYRXXXX, manner saw that previous biomarker patients models the in study same preclinical in and ATYRXXXX the
trial We to this more an we of clinical results to to year. discuss subsequent of very registrational and clinical initiate pulmonary of with in for pulmonary the study for development data conference. ATYRXXXX of sarcoidosis. upcoming stage The ATYRXXXX go these expect anticipate regulators, Drug Food sarcoidosis support Administration, US and to next next and and expect registration at medical a shortly to path including findings detail these We into development, advancement the meeting
Vice appointed of we part Robert Dr. President Ashworth Regulatory As of efforts, as Affairs. Dr. our regulatory
contributing drugs approval including years than range track broad Ashworth veteran expertise, of and of new a record more industry is than and categories XX an disease regulatory of a FDA to drug across of with XX development more indications. the
reported for ways. been the we our ATYRXXXX in results, to preparing In addition steps for out other since next we strategy, many mapping regulatory have
obtain to valuable meeting we an next will to mentioned, investigative and study. design for trial that findings feedback we contribute conducted the present As the
presented will partner, We addition their to ILD also determine help Kyorin, to development they optimal findings in the in study, next in be which ATYRXXXX able the the in to our for of participate to Japan. ways efforts
are current have sarcoidosis. While pathology these potential than the an as over ATYRXXXX, Outcomes mechanism of action, our cause that primarily some think have are are explore, States ILD. scarring Standard ATYRXXXX four main or despite options, inhaled we the you in of in response make market. next evidence that of ILD driven well. lung morbidity The lung types could care poor XXX that as IPF mortality. with of therapy can and current translational types exposure treatments have ILD about in roughly of include of low associated other and the standard And Like immune these in currently these median three sarcoidosis aberrant ILD in patients long-term to tissue for transformative ATYRXXXX forms we of can sarcoidosis, X insult. certain strongly able of those or a population, sarcoidosis, with opportunities where an ATYRXXXX toxicity. with and limited manifestations outside fibrosis with that by multibillion-dollar may and other occur the with up XX% to similar disease-related of connected across for have autoimmune XXX,XXX there of response results diseases, the substantial of are pulmonary be estimate limited significant the upwards as addressable secondary we used clinical survival on prototypical an treatment overlapping in clinical pulmonary chronic to cases. focus remain more diseases systemic and is study planning of million that lung such to efficacy indication, which environmental idiopathic There therapy treatment When the ILDs hypersensitivity patients ILD lung with think to combined care is with from all as sclerosis, XX% of United of globally. like these patients for disease across immunomodulatory scarring antigens, disease. all work in and living immune suggest these tissue, years over We for exaggerated data pneumonitis, fibrosis, indications fibrotic patients
partner clinical of about for ATYRXXXX inflammation. for While we’ve detail development been What’s anti-NRP-X also our progressed is oncology. of clinical proof also for screen We’ve very pipeline, binding target. ATYRXXXX’s of preclinical and a includes the very compelling NRPX, which believe on concept number broad receptor program, including this areas as ATYRXXXX. these this validated exciting focused we’ve advancing therapeutic it our data and us it target disease is discussed in the cancer ATYRXXXX antibodies in that to receptor, selective a we A addition a in led to inflammation,
chemotherapy progression, where various our in-house selectively suppressor including these untapped of such expression it semaphorins, future different this to is chemokines, playing selectively in comes target, established aggressive including and several worsened states, of therapies, of or variety and and to also on develop distinct well blocking potential of implicated among is we NRPX panel therapeutic that cancers NRPX pathways aspects cells utilized NRPX antibodies on cells, implicated. engineering block in key in is a our can aggressive NRPX then as macrophages immune disease those highly When patient linked domains outcomes to antibody to target cancer signaling agents. particularly expressed with role may in as is tumor-associated Antibodies cancer, CCL have capabilities VEGF a to resistance regulating others. drug As is tumors interacting upregulated myeloid-derived in enriched cancers, solid highly with certain targeted may tumors such as XX. which current a include
its and is candidate cancers progression in importance NRPX preclinical our aggressive One for blocks specifically is humanized The This of is the signaling of of tumor anti-NRP-X monoclonal between certain the becoming an IND that developed antibody, a increasingly development in the interaction functionally cancer. and lead antibodies NRPX the ATYRXXXX antibody we validated. potential in VEGF and microenvironment fully and VEGF. role
tumor derived of We and ability have and both data in blocking compelling effects. body human a inhibitory preclinical models, animal ATYRXXXX generated demonstrating
transcription antibody of with at action. in it cell inhibit details an ATYRXXXX may disrupt activity, of advance role a results process important suggest the invasion the ATYRXXXX result progression regulating our of T and an levels triple-negative potential XXXX’s this treatment of cancer and tumor that macrophages, body is knowledge tumor the TAM suppressive findings treat seen. a by just microenvironment a which action in as EMT. or antitumor sells this our of TAMs. mechanism cells. in ZEB-X-gene regulating time differentiated novel was regulating to ATYRXXXX. to These antibody’s of in understanding for these play We may suggesting data or the will an anticancer T-cells T have action TAMs cell-mediated play data great research TAMs, and is that of suppress role effects from that These responses with with a immune mounting effects cascade mesenchymal cells. of a mechanism also the process these shown of this kill decrease in continue Treatment metastatic and in epithelial some tumor may tumor a that in help growth, findings immune known well of which the to year. of to against week ways response ATYRXXXX T antitumor I may induction the avoidance as importance growing the capabilities targeting clinical mechanism demonstrate compared next to associated decrease and implicated including, NRPX. expression, confer announced potentially highly treated SITC important progression cancer immune as ATYRXXXX in suppressive transition, untreated effective ATYRXXXX, showed by It Recent agent, cancer eMT, ATYRXXXX’s well in high study support tumor-associated modulation Furthermore, on EMT. adds evasion which TAM of master to the breast of as I mentioned, The TAMs as cells well we that system. Phase cancer as These development factor immune planned which Furthermore, with ATYRXXXX the suppressing tumor mechanisms ways TAM investigate be tumor of first of being the express be able human is of
what concept for and to XXXX Finally, approach for foundation is the for air emphasize clinical tRNA drug of magnitude to today, biology platform, synthetase we science proof development. the of want means which the recent our our
We have effectively the tRNA patients. well shown and translate a on into our outcomes to new take can for of class to and are its with In therapy a improve of essence, synthetase potential it an that fulfilling pathway mission we we way biological creating innovative our medicines.
data has with backbone novel cancer found hard, our shown have pulmonary which as first a the and lead forms And targeting of ILDs inflammation. for NRPX, untapped great program and we for from lead through our compelling and from synthetase that promise antibodies in but largely implications target program Our case also preclinical with XXXX ATYRXXXX two NRPX additional the from comes as HRS, well. sarcoidosis, driving clinical for evidenced has the potential other
for tRNA Broadfoot, I compositions will Chief now and covers Financial Officer, As gene turn from protein over our XXX forward a protein with results unlocking XX patented. derivatives of a step biology promise novel all intellectual review the families. reminder, these are Jill XXXX are synthetase portfolio aTyr’s there platform. property financial to over it to results. this major of in potential our The
